跳至主要内容
临床试验/NCT03694535
NCT03694535已完成不适用

Intravesical Mitomycin-C With Bladder Wall Hyperthermia in Intermediate and High Risk Non-muscle Invasive Bladder Cancer

TC Erciyes University1 个研究点 分布在 1 个国家目标入组 44 人开始时间: 2012年1月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
44
试验地点
1
主要终点
Recurrence

研究概览

简要总结

To investigate effect of intravesical mitomycin-C(MMC) applied with bladder wall thermotherapy system on reccurrence and progression status of intermediate and high risk non muscle invasive bladder cancer

详细描述

Before the application of TCT, complete transurethral bladder tumour resection (TURBT) was performed. RE-TURBT was conducted within 4 weeks for patients with initial T1 pathology. The first TCT instillation was applied at 1mo following the TURBT or the RE-TURBT.

Thermochemotherapy application and treatment schedule:

The bladder wall TCT (BWT) system (Elmedical Ltd, Hod-Hasharon, Israel) was used as a conductive heating modality. MMC (40 mg; MMC Kyowa Hakko Kogyo Co., Ltd., Tokyo, Japan) was mixed with 50 mL of 0.9% saline solution and applied using a disposable silicone 20Fr 3-way TCT catheter (UniThermia catheter; Elmedical Ltd). In each session, the bladder was irrigated with MMC solution at 42°C-45°C for 45 min via the BWT system. The treatment schedule consisted of an initial 6-week instillation, followed by control cystoscopy and urine cytology in the 3rd month and monthly instillations up to 1 yr. Urine cytology and cystoscopy were performed every three months. The samples were collected from the suspected areas during cystoscopy. At the end of the first year, control cystoscopy with random bladder biopsies was conducted. During the second year, routine controls were conducted every three months. Subsequently, follow-ups were performed every six months. In case of development of any complication in a patient, TCT was discontinued. Before each instillation of TCT, clear urine cultures were obtained from all patients. No prophylactic anticholinergic was administered prior to intravesical TCT. If TUR BT pathology was Ta or T1 during the follow-up, it was accepted as a recurrence. If it was CIS or T2, it was accepted as a progression. All adverse events observed during the study were recorded according to the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 [9. All study protocols were approved by the local ethical committee at our institution. An informed consent was obtained from all patients.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Prevention
盲法
None

入排标准

性别
All
接受健康志愿者

入选标准

  • newly diagnosed or followed as recurrent intermediate-risk non muscle invasive non muscle invasive bladder cancer according to the criteria of European Association of Urology.
  • newly diagnosed or followed as recurrent high-risk non muscle invasive non muscle invasive bladder cancer according to the criteria of European Association of Urology.
  • pathology of urothelial carcinoma

排除标准

  • Low bladder capacity (<150ml)
  • increased post voiding residual urine (>150ml)
  • untreatable or uncontrollable urinary tract infection
  • history of urethral stricture
  • presence of bladder diverticula larger than 1 cm
  • pathology other than urothelial carcinoma
  • WHO (World Health Organization) performance status > 2
  • upper urinary tract urothelial carcinoma diagnosis

研究组 & 干预措施

Bladder wall thermochemotherapy

Experimental

Mitomycin-C application with bladder wall thermochemotherapy system after TUR bladder tumor in intermediate and high risk non muscle invasive bladder cancer

干预措施: bladder wall thermotherapy with Mitomycin-c (Drug)

结局指标

主要结局

Recurrence

时间窗: From the beginning of thermochemoterapy until the date of first documented recurrence assessed up to 2 years

recurrence rate of non muscle invasive bladder cancer during or after treatment

Progression rate

时间窗: From the beginning of thermochemoterapy until the date of first documented progression assessed up to 2 years

progression rate of non muscle invasive bladder cancer during or after treatment ( progress to muscle invasive stage or carcinoma in situ)

次要结局

  • Side effects(From the beginning of thermochemoterapy until the date of first documented side effect(s) assessed up to 2 years)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Abdullah Demirtas

Md, Assoc. Prof.

TC Erciyes University

研究点 (1)

Loading locations...

相似试验